Complicated urinary tract infections (cUTIs) represent one of the most challenging and rapidly evolving areas of infectious disease management. Often more severe and harder to treat than standard UTIs, cUTIs are associated with underlying structural or functional abnormalities of the …
Fibrosis remains one of the greatest unmet needs in inflammatory bowel disease (IBD), contributing to irreversible structural bowel damage, complications, and long-term morbidity despite advances in anti-inflammatory therapies. Many gastroenterologists and multidisciplinary gastrointestinal (GI) care teams lack confidence in recognizing …
Despite the availability of a safe and effective recombinant zoster vaccine (RZV) for herpes zoster (HZ), vaccination uptake and series completion remain insufficient, leaving many at-risk individuals—particularly older adults, immunocompromised patients, and underserved populations—vulnerable to preventable disease and its impact …
What if the neuropathy in front of you isn’t what it seems? Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common immune-mediated peripheral neuropathy, yet it remains widely underrecognized. Because its symptoms mimic other neuropathies, CIDP is too often misdiagnosed …
Lupus nephritis (LN) is one of the most consequential organ manifestations of systemic lupus erythematosus (SLE), occurring in approximately 40% to 60% of patients, most often within the first 5 years of diagnosis, and progressing to end-stage kidney disease in …
Obesity is transforming the landscape of inflammatory bowel disease (IBD), shaping disease activity, treatment response, and long-term prognosis. As evidence reveals the impact of excess weight on biologic and JAK inhibitor effectiveness, emerging anti-obesity therapies, including GLP-1 receptor agonists, are …
Obesity is transforming the landscape of inflammatory bowel disease (IBD), shaping disease activity, treatment response, and long-term prognosis. As evidence reveals the impact of excess weight on biologic and JAK inhibitor effectiveness, emerging anti-obesity therapies, including GLP-1 receptor agonists, are …
Extraintestinal manifestations (EIMs) affect up to one-third of patients with inflammatory bowel disease (IBD) and can significantly contribute to morbidity, impaired quality of life, and long-term disease burden, yet they remain inconsistently recognized and managed in clinical practice. Many gastroenterologists …
Although treatment advances in inflammatory bowel disease (IBD) have improved symptom control, many patients continue to experience progressive structural bowel damage and systemic complications that are not adequately addressed in routine care. Gastroenterologists and multidisciplinary gastrointestinal (GI) care teams often …